Cite
HARVARD Citation
Elsamany, S. et al. (2021). Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients. Expert review of pharmacoeconomics & outcomes research. pp. 511-518. [Online].